Zydus Lifesciences has informed that, Sentynl Therapeutics Inc., USA, a wholly owned subsidiary (‘Sentynl’) of the Company has acquired worldwide proprietary rights to Zokinvy® (lonafarnib) from Eiger Biopharmaceuticals Inc., USA (‘Seller’), pursuant to an asset purchase agreement (‘APA’), adding to portfolio of biopharmaceuticals for rare and ultra-rare diseases. Zokinvy® is approved in the U.S. (2020), European Union and Great Britain (2022), and Japan (2024) for the treatment of Progeria, a collection of ultra-rare, fatal, genetic premature aging diseases that accelerate mortality in young patients. Necessary details as stipulated under regulation 30 of the Listing Regulations read with para 5 of Part II of the SEBI Circular dated July 13, 2023 are provided in Annexure- ‘1’.
The above information is a part of company’s filings submitted to BSE.
